News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Affymax, Inc. To Present At Biotechnology Industry Organization (BIO) CEO & Investor Conference February 23, 2005

10/19/2005 5:12:45 PM

PALO ALTO, Calif., Feb. 17 /PRNewswire/ -- Affymax, Inc. today announced that Arlene M. Morris, the company's president and chief executive officer, will present at the BIO CEO & Investor Conference on Wednesday, February 23rd at 2:00 p.m. ET in New York, NY.

Ms. Morris will discuss Affymax's significant progress transforming its leading-edge research organization into a highly productive drug development company focused on the advancement of novel peptide-based drugs against validated targets. Specifically, she will describe the preliminary clinical trial data and plans for its lead product candidate, Hematide(TM), a peptide-based erythropoiesis stimulating agent (ESA) that stimulates production of red blood cells. The company recently completed a Phase 1 dose-finding clinical trial with Hematide, and expects to initiate several Phase 2 studies this year in renal disease and cancer. She also will address the status of the emerging pipeline with emphasis on the company's peptidic G-CSF receptor agonist program, which the company anticipates will enter clinical trials next year.

About Affymax

Affymax, Inc. is a development stage pharmaceutical company that is developing novel peptide drugs for the treatment of various blood, cancer and kidney diseases. Affymax is building a rich pipeline of novel peptide drugs against clinically validated targets that will provide superior product profiles over therapeutic proteins. Advantages of peptide-based drugs can include reduced immunogenicity, improved dosing convenience, flexible storage and uncomplicated chemical synthesis. Hematide(TM), the company's first product to enter the clinic, is a peptide-based drug designed to stimulate the production of red blood cells. It is being developed for various indications, including the treatment of anemia associated with chronic kidney disease and cancer. The company is also advancing a peptide that is an agonist of the G-CSF receptor and has entered into a research collaboration with EntreMed for the synthesis and development of novel peptides that mimic the function of certain fragments of tissue factor pathway inhibitors. For more information go to

Affymax, Inc.

CONTACT: Mary Fermi, Senior Director, of Affymax, Inc., +1-650-812-8700,or

Read at

comments powered by Disqus